Skip to content

Study · Animal study (in vivo) · mouse · 2021

4 results

The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro and Increases Bone Mineral Density in Mice.

Awida Z, Bachar A, Saed H, Gorodov A, Ben-Califa N, Ibrahim M, Kolomansky A, Iden JA, Graniewitz Visacovsky L, Liron T, Hiram-Bab S, Brines M, Gabet Y, Neumann D

International journal of molecular sciences21 Dec 2021Cited by 6 (Europe PMC)

PMID35008482 (opens in a new tab)PMCIDPMC8744753 (opens in a new tab)DOI10.3390/ijms23010055 (opens in a new tab)PepBankPUB-35008482
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

The two erythropoietin (EPO) receptor forms mediate different cellular responses to erythropoietin. While hematopoiesis is mediated via the homodimeric EPO receptor (EPOR), tissue protection is conferred via a heteromer composed of EPOR and CD131. In the skeletal system, EPO stimulates osteoclast precursors and induces bone loss. However, the underlying molecular mechanisms are still elusive. Here, we evaluated the role of the heteromeric complex in bone metabolism in vivo and in vitro by using Cibinetide (CIB), a non-erythropoietic EPO analogue that exclusively binds the heteromeric receptor. CIB is administered either alone or in combination with EPO. One month of CIB treatment significantly increased the cortical (~5.8%) and trabecular (~5.2%) bone mineral density in C57BL/6J WT female mice. Similarly, administration of CIB for five consecutive days to female mice that concurrently received EPO on days one and four, reduced the number of osteoclast progenitors, defined by flow cytometry as Lin-CD11b-Ly6Chi CD115+, by 42.8% compared to treatment with EPO alone. In addition, CIB alone or in combination with EPO inhibited osteoclastogenesis in vitro. Our findings introduce CIB either as a stand-alone treatment, or in combination with EPO, as an appealing candidate for the treatment of the bone loss that accompanies EPO treatment.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In female C57BL/6J mice, one month of cibinetide significantly increased cortical bone mineral density by about 5.8%.

    In plain wordsIn female mice, one month of cibinetide raised the density of the outer bone layer.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    IncreaseCortical bone mineral density
    Study

    mousen: not reported in source

    C57BL/6J WT female mice
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 1 monthAs given in this study (mouse).

    Measurements

    Cortical BMD increase
    ≈ 5.8%
    CIB 1 month

    Source sentences

    Summary
    One month of CIB treatment significantly increased the cortical (~5.8%) and trabecular (~5.2%) bone mineral density in C57BL/6J WT female mice.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In female C57BL/6J mice, one month of cibinetide significantly increased trabecular bone mineral density by about 5.2%.

    In plain wordsIn female mice, one month of cibinetide raised the density of the inner spongy bone.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    IncreaseTrabecular bone mineral density
    Study

    mousen: not reported in source

    C57BL/6J WT female mice
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 1 monthAs given in this study (mouse).

    Measurements

    Trabecular BMD increase
    ≈ 5.2%
    CIB 1 month

    Source sentences

    Summary
    One month of CIB treatment significantly increased the cortical (~5.8%) and trabecular (~5.2%) bone mineral density in C57BL/6J WT female mice.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In female mice given EPO, five days of cibinetide reduced the number of osteoclast progenitors by 42.8% compared with EPO alone.

    In plain wordsIn female mice given EPO, cibinetide lowered the number of bone-resorbing cell precursors compared with EPO alone.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    DecreaseOsteoclast progenitor number
    Study

    mousen: not reported in source

    C57BL/6J WT female mice
    Comparator
    EPO alone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 5 consecutive daysAs given in this study (mouse).

    Measurements

    Osteoclast progenitor reduction
    42.8%
    CIB plus EPO versus EPO alone

    Source sentences

    Summary
    Similarly, administration of CIB for five consecutive days to female mice that concurrently received EPO on days one and four, reduced the number of osteoclast progenitors, defined by flow cytometry as Lin-CD11b-Ly6Chi CD115+, by 42.8% compared to treatment with EPO alone.
  4. 04LabIn vitro (cells)Mechanism

    In vitro, cibinetide alone or combined with EPO inhibited osteoclastogenesis.

    In plain wordsIn lab tests, cibinetide, alone or with EPO, reduced the formation of bone-resorbing cells.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    DecreaseOsteoclastogenesis in vitro
    Study

    n: not reported in source

    In vitro osteoclastogenesis
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In addition, CIB alone or in combination with EPO inhibited osteoclastogenesis in vitro.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.